Suppr超能文献

生物可吸收冠状动脉支架血栓形成:多中心临床特征、机制和预测因素的综合分析。

Bioresorbable Coronary Scaffold Thrombosis: Multicenter Comprehensive Analysis of Clinical Presentation, Mechanisms, and Predictors.

机构信息

Department of Cardiology, University & Hospital Fribourg, Fribourg, Switzerland.

Department of Cardiology, Luzerner Kantonsspital, Luzern, Switzerland.

出版信息

J Am Coll Cardiol. 2016 Mar 1;67(8):921-931. doi: 10.1016/j.jacc.2015.12.019.

Abstract

BACKGROUND

Recent reports suggest an elevated incidence of bioresorbable vascular scaffold (BVS) thrombosis (scaffold thrombosis [ScT]).

OBJECTIVES

This study investigated occurrence rates, clinical and angiographic characteristics, and possible mechanisms of ScT in all-comer patients undergoing BVS implantation at 2 German and 2 Swiss hospitals.

METHODS

A total of 1,305 consecutive patients (mean age 64 years, 78% male) who received 1,870 BVS (mean 1.4 ± 0.8 BVS/patient) were enrolled. Clinical/procedural characteristics, mortality, and ScT data at 485 days (range 312 to 652 days) were examined.

RESULTS

ScT occurred in 42 patients. The incidence of probable and definite ScT was 1.8% at 30 days and 3.0% at 12 months, without differences among centers (p = 0.60). A total of 22 (52%) ScTs presented as ST-segment elevation myocardial infarction and 6 (17%) as sudden cardiac death. In multivariable analysis, ostial lesions (p = 0.049) and impaired left ventricular ejection fraction (p = 0.019) were independently associated with ScT. Nine (21%) of the ScTs occurred in patients who had suspended dual antiplatelet therapy, in 6 cases prematurely. Lower post-procedural minimum lumen and reference vessel diameters were hallmarks of ScT (all p < 0.0001). The risk of ScT appeared to rapidly increase for post-procedural minimum lumen diameters below 2.4 mm (for the 2.5- to 3.0-mm BVS) and 2.8 mm (for the 3.5-mm BVS). When a BVS-specific implantation strategy was implemented, 12-month ScT rates fell from 3.3% to 1.0%, an effect that remained significant when adjusted for multivariable propensity score (p = 0.012; hazard ratio: 0.19; 95% confidence interval: 0.05 to 0.70).

CONCLUSIONS

The 12-month incidence of ScT reached 3% and could be significantly reduced when an optimized implantation strategy was employed. (retrospective multicentric registry and Mainz Intracoronary Database. The Coronary Slow-flow and Microvascular Diseases Registry [MICAT]; NCT02180178).

摘要

背景

最近的报告表明,生物可吸收血管支架(BVS)血栓形成(支架血栓形成[ScT])的发生率升高。

目的

本研究旨在调查德国和瑞士的 2 家医院共收治的所有患者中 BVS 植入术后 ScT 的发生率、临床和血管造影特征以及可能的发病机制。

方法

共纳入 1305 例连续患者(平均年龄 64 岁,78%为男性),共植入 1870 枚 BVS(平均每名患者植入 1.4±0.8 枚 BVS)。在 485 天(312 至 652 天)时评估临床/手术特征、死亡率和 ScT 数据。

结果

42 例患者发生 ScT。30 天时可能和确定的 ScT 发生率为 1.8%,12 个月时为 3.0%,各中心之间无差异(p=0.60)。22 例(52%)ScT 表现为 ST 段抬高型心肌梗死,6 例(17%)为心脏性猝死。多变量分析显示,开口病变(p=0.049)和左心室射血分数受损(p=0.019)与 ScT 独立相关。9 例(21%)ScT 发生在中断双联抗血小板治疗的患者中,其中 6 例过早中断。支架内最小管腔直径和参考血管直径减小是 ScT 的标志(均 p<0.0001)。支架内最小管腔直径低于 2.4mm(2.5-3.0mm BVS)和 2.8mm(3.5mm BVS)时,ScT 的风险似乎迅速增加。当采用特定于 BVS 的植入策略时,12 个月时 ScT 发生率从 3.3%降至 1.0%,经多变量倾向评分调整后仍有显著差异(p=0.012;危险比:0.19;95%置信区间:0.05 至 0.70)。

结论

采用优化的植入策略时,12 个月时 ScT 的发生率可显著降低至 3%。(回顾性多中心登记和 Mainz 冠状动脉内数据库。冠状动脉慢血流和微血管疾病登记[MICAT];NCT02180178)。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验